Current Concepts

Pharmacologic Agents in the Management of Pheochromocytoma

Authors: DAVID JUAN MD

Abstract

ABSTRACTMedical management of pheochromocytoma involves the use of many therapeutic agents. Phenoxybenzamine HCl (Dibenzyline), an alpha-adrenergic blocking agent, at 40 to 80 mg per day can control the disease in most patients. Use of this drug up to the time of operation is controersial. Beta-adrenergic receptor blockade with propranolol is indicated only after adequate alpha-adrenergic blockade in patients with tachycardia and catecholamine-induced arrhythmias. Alpha-methylparatyrosine (Metyrosine), which decreases catecholamine synthesis, is a new drug recently released for the treatment fo pheochromocytoma when surgery is contraindicated or in cases of malignant pheochromocytoma. The use of a combination of anesthetic agents, such as nitrous oxide, thipental, narcotic, and enflurne, ensures smooth induction of anesthesia in most cases. Careful and prompt control of hypertensive crises with sodium nitroprusside and of arrhythmias with propranolol and lidocaine are critical to the success of surgery.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References